Literature DB >> 3306682

Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease.

R B Levene, F M Booyse, J Chediak, T S Zimmerman, D M Livingston, D C Lynch.   

Abstract

Studies were conducted to characterize the biosynthesis of von Willebrand factor (vWf) by cultured endothelial cells (EC) derived from the umbilical vein of a patient with type IIA von Willebrand disease. The patient's EC, compared with those from normal individuals, produced vWf that had decreased amounts of large multimers and an increase in rapidly migrating satellite species, features characteristic of plasma vWf from patients with type IIA von Willebrand disease. The type IIA EC did produce a full spectrum of vWf multimers in both cell lysates and postculture medium, although the relative amounts of the largest species were decreased. The large multimers were degraded in conjunction with the appearance of rapidly migrating satellites that contained approximately equal to 170-kDa proteolytic fragments, suggesting that this patient's functional defect is due to abnormal proteolysis and not to a primary failure of vWf subunit oligomerization. Moreover, the observed degradation appears to result from an abnormal vWf molecule and not elevated protease levels. These results suggest that this patient's von Willebrand disease phenotype is caused by increased proteolytic sensitivity of his vWf protein.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3306682      PMCID: PMC299116          DOI: 10.1073/pnas.84.18.6550

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain.

Authors:  D D Wagner; V J Marder
Journal:  J Biol Chem       Date:  1983-02-25       Impact factor: 5.157

2.  Characterization and properties of cultured human von Willebrand umbilical vein endothelial cells.

Authors:  F M Booyse; A J Quarfoot; J Chediak; M B Stemerman; T Maciag
Journal:  Blood       Date:  1981-10       Impact factor: 22.113

3.  Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.

Authors:  Z M Ruggeri; P M Mannucci; R Lombardi; A B Federici; T S Zimmerman
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

Review 4.  Factor VIII/von Willebrand factor.

Authors:  T S Zimmerman; Z M Ruggeri; C A Fulcher
Journal:  Prog Hematol       Date:  1983

5.  Human endothelial cells: use of heparin in cloning and long-term serial cultivation.

Authors:  S C Thornton; S N Mueller; E M Levine
Journal:  Science       Date:  1983-11-11       Impact factor: 47.728

6.  Subunit composition of oligomeric human von Willebrand factor.

Authors:  D C Lynch; T S Zimmerman; E P Kirby; D M Livingston
Journal:  J Biol Chem       Date:  1983-11-10       Impact factor: 5.157

7.  Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed.

Authors:  P Gunning; P Ponte; H Okayama; J Engel; H Blau; L Kedes
Journal:  Mol Cell Biol       Date:  1983-05       Impact factor: 4.272

8.  Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.

Authors:  D D Wagner; J B Olmsted; V J Marder
Journal:  J Cell Biol       Date:  1982-10       Impact factor: 10.539

9.  Serial propagation of human endothelial cells in vitro.

Authors:  T Maciag; G A Hoover; M B Stemerman; R Weinstein
Journal:  J Cell Biol       Date:  1981-11       Impact factor: 10.539

10.  Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization.

Authors:  D D Wagner; V J Marder
Journal:  J Cell Biol       Date:  1984-12       Impact factor: 10.539

View more
  6 in total

Review 1.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

2.  Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.

Authors:  D Ginsburg; B A Konkle; J C Gill; R R Montgomery; P L Bockenstedt; T A Johnson; A Y Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Proteolytic processing of von Willebrand factor subunit: heterogeneity in type-IIA von Willebrand disease.

Authors:  J Batlle; J Lasierra; A F Villamor; J L Navarro; A Pardo; M Campos; B Justiça; M F López Fernández
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

4.  O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b.

Authors:  J A Carew; S M Quinn; J H Stoddart; D C Lynch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

5.  von Willebrand factor synthesized by endothelial cells from a patient with type IIB von Willebrand disease supports platelet adhesion normally but has an increased affinity for platelets.

Authors:  P G de Groot; A B Federici; H C de Boer; P d'Alessio; P M Mannucci; J J Sixma
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 6.  Von Willebrand Disease: From In Vivo to In Vitro Disease Models.

Authors:  Suzan de Boer; Jeroen Eikenboom
Journal:  Hemasphere       Date:  2019-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.